OTCMKTS:ENZN - Enzon Pharmaceuticals Stock Price, Price Target & More

$0.2610 0.00 (0.00 %)
(As of 04/22/2018 04:00 PM ET)
Previous Close$0.2610
Today's Range$0.2610 - $0.2625
52-Week Range$0.03 - $0.40
Volume401 shs
Average Volume40,543 shs
Market Capitalization$11.54 million
P/E Ratio2.37
Dividend YieldN/A
Beta0.82

About Enzon Pharmaceuticals (OTCMKTS:ENZN)

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. The company's marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular wet age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohn's disease. Enzon Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Cranford, New Jersey.

Receive ENZN News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolOTCMKTS:ENZN
CUSIP29390410
Phone732-980-4500

Debt

Debt-to-Equity RatioN/A
Current Ratio21.03%
Quick Ratio21.03%

Price-To-Earnings

Trailing P/E Ratio2.37
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.38 million
Price / Sales1.38
Cash Flow$0.1231 per share
Price / Cash2.12
Book Value$0.21 per share
Price / Book1.24

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$5.44 million
Net Margins64.98%
Return on Equity49.56%
Return on Assets47.88%

Miscellaneous

Employees5
Outstanding Shares44,220,000

How to Become a New Pot Stock Millionaire

Enzon Pharmaceuticals (OTCMKTS:ENZN) Frequently Asked Questions

What is Enzon Pharmaceuticals' stock symbol?

Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN."

How often does Enzon Pharmaceuticals pay dividends? What is the dividend yield for Enzon Pharmaceuticals?

Enzon Pharmaceuticals declared a dividend on Tuesday, August 15th. Shareholders of record on Wednesday, August 30th will be given a dividend of $0.15 per share on Thursday, September 28th. The ex-dividend date of this dividend is Friday, September 29th. View Enzon Pharmaceuticals' Dividend History.

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals (OTCMKTS:ENZN) issued its quarterly earnings results on Wednesday, August, 10th. The biotechnology company reported $0.02 earnings per share for the quarter. The biotechnology company had revenue of $2.27 million for the quarter. Enzon Pharmaceuticals had a net margin of 64.98% and a return on equity of 49.56%. View Enzon Pharmaceuticals' Earnings History.

When is Enzon Pharmaceuticals' next earnings date?

Enzon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for Enzon Pharmaceuticals.

Who are some of Enzon Pharmaceuticals' key competitors?

Who are Enzon Pharmaceuticals' key executives?

Enzon Pharmaceuticals' management team includes the folowing people:
  • Mr. Andrew Rackear J.D., CEO & Sec. (Age 64)
  • Mr. Richard L. Feinstein CPA, VP of Fin. & CFO (Age 75)

Has Enzon Pharmaceuticals been receiving favorable news coverage?

News articles about ENZN stock have trended somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Enzon Pharmaceuticals earned a news sentiment score of 0.16 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 47.19 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Enzon Pharmaceuticals' major shareholders?

Enzon Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include COUCHMAN JONATHAN (10.60%) and COUCHMAN PARTNERS LP (10.60%). View Institutional Ownership Trends for Enzon Pharmaceuticals.

How do I buy shares of Enzon Pharmaceuticals?

Shares of ENZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzon Pharmaceuticals' stock price today?

One share of ENZN stock can currently be purchased for approximately $0.2610.

How big of a company is Enzon Pharmaceuticals?

Enzon Pharmaceuticals has a market capitalization of $11.54 million and generates $8.38 million in revenue each year. Enzon Pharmaceuticals employs 5 workers across the globe.

How can I contact Enzon Pharmaceuticals?

Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at 732-980-4500 or via email at [email protected]


MarketBeat Community Rating for Enzon Pharmaceuticals (ENZN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  80
MarketBeat's community ratings are surveys of what our community members think about Enzon Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Enzon Pharmaceuticals (OTCMKTS:ENZN) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/22/2016 forward)

Earnings

Enzon Pharmaceuticals (OTCMKTS:ENZN) Earnings History and Estimates Chart

Earnings by Quarter for Enzon Pharmaceuticals (OTCMKTS:ENZN)

Enzon Pharmaceuticals (OTCMKTS ENZN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018        
8/10/2017Q2 2017$0.09$6.78 millionViewN/AView Earnings Details
5/11/2017Q1 2017$0.01$1.44 millionViewN/AView Earnings Details
3/24/2017Q4 2016($0.10)$0.85 millionViewN/AView Earnings Details
11/10/2016Q3 2016$0.02$1.99 millionViewN/AView Earnings Details
8/10/2016Q3 2016$0.02$2.27 millionViewN/AView Earnings Details
5/9/2016Q1 2016$0.03$3.27 millionViewN/AView Earnings Details
3/21/2016Q4 2015$0.28$3.16 millionViewN/AView Earnings Details
11/6/2015Q3 2015($0.04)$3.84 millionViewN/AView Earnings Details
8/7/2015Q2 2015$0.09$5.19 millionViewN/AView Earnings Details
5/13/2015Q1 2015$0.16$5.26 millionViewN/AView Earnings Details
3/5/2015Q4 2014$0.13$6.27 millionViewN/AView Earnings Details
11/6/2014Q3 2014$0.17$8.16 millionViewN/AView Earnings Details
8/8/2014Q2 2014$0.16$7.77 millionViewN/AView Earnings Details
5/9/2014Q1 2014$0.19$8.98 millionViewN/AView Earnings Details
3/14/2014Q4 2013$0.12$7.43 millionViewN/AView Earnings Details
11/12/2013Q3 2013$0.13$8.83 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.09$8.06 millionViewN/AView Earnings Details
5/10/2013Q1 2013$0.05$10.40 million$10.18 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.11)$10.01 million$10.65 millionViewN/AView Earnings Details
10/31/2012Q3 2012$0.02$0.08ViewN/AView Earnings Details
8/1/2012Q2 2012($0.02)ViewN/AView Earnings Details
5/2/2012Q1 2012($0.02)ViewN/AView Earnings Details
3/12/2012Q4 2011($0.08)ViewN/AView Earnings Details
11/3/2011Q3 2011($0.14)ViewN/AView Earnings Details
8/4/2011Q2 2011($0.12)ViewN/AView Earnings Details
5/6/2011Q1 2011($0.01)($0.07)ViewN/AView Earnings Details
2/17/2011Q4 2010($0.08)($0.13)ViewN/AView Earnings Details
11/2/2010Q3 2010($0.04)($0.13)ViewN/AView Earnings Details
8/3/2010Q2 2010($0.06)($0.08)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.15)($0.13)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.04)($0.11)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.07)$0.04ViewN/AView Earnings Details
2/19/2009Q4 2008($0.13)($0.01)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.15)($0.05)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.10)($0.01)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.08)$0.03ViewN/AView Earnings Details
2/14/2008Q4 2007($0.16)$0.02ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Enzon Pharmaceuticals (OTCMKTS:ENZN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/15/2017$0.159/29/20178/30/20179/28/2017
12/7/2015special$0.2512/30/201512/14/201512/29/2015
7/7/2015special$0.508/13/20157/21/20158/12/2015
12/9/2014special$0.101/8/20151/12/20151/28/2015
12/9/2013special$0.4512/24/201312/16/201312/23/2013
4/23/2013special$1.605/3/20135/7/20136/4/2013
(Data available from 1/1/2013 forward)

Insider Trades

Enzon Pharmaceuticals (OTCMKTS ENZN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 0.09%
Insider Trading History for Enzon Pharmaceuticals (OTCMKTS:ENZN)

Enzon Pharmaceuticals (OTCMKTS ENZN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/28/2016Carl C IcahnMajor ShareholderBuy694,023$0.41$284,549.43View SEC Filing  
9/19/2013Robert LebuhnDirectorSell55,926$1.72$96,192.72View SEC Filing  
8/10/2012Robert LebuhnDirectorSell1,933$6.58$12,719.14View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Enzon Pharmaceuticals (OTCMKTS ENZN) News Headlines

Source:

SEC Filings

Enzon Pharmaceuticals (OTCMKTS:ENZN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Enzon Pharmaceuticals (OTCMKTS:ENZN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Enzon Pharmaceuticals (OTCMKTS ENZN) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.